Dupixent Lawsuits Centralized in New Jersey: What the MDL Means

What Changed in June 2026

In June 2026, the Judicial Panel on Multidistrict Litigation centralized federal lawsuits alleging that Dupixent (dupilumab) is linked to cutaneous T-cell lymphoma. They now sit in one proceeding, MDL 3180, in the U.S. District Court for the District of New Jersey. The named defendants are Sanofi and Regeneron, the companies behind the drug.

If you took Dupixent for eczema or atopic dermatitis and were later diagnosed with a lymphoma of the skin, this order will shape how a federal claim moves from here. It is also easy to misread. Some coverage makes it sound as if the panel looked at the science and found something.

It did not.

What an MDL Does

A multidistrict litigation brings cases that share common factual questions before a single federal judge for the pretrial phase. In practice that judge oversees:

• Discovery, meaning the exchange of company documents and the depositions of Sanofi and Regeneron witnesses, so the same people are not questioned in dozens of separate courtrooms
• Disputes over which expert opinions a jury will be allowed to hear
• The forms and medical records each plaintiff must submit early in the case
• Scheduling, including any early test trials (often called bellwethers) the court decides to set

Each case stays individual. An MDL works differently from a class action. Nobody is appointed to speak for you as a class representative, and your own diagnosis, treatment dates and medical records will carry your claim.

If a case is not resolved during the MDL, it can be sent back to the court where it was originally filed for trial.

What Centralization Does Not Mean

The panel’s order is a case-management decision. It reflects a judgment that handling these cases together is more efficient than handling them apart. It does not find that Dupixent causes lymphoma or that either company did anything wrong.

It also says nothing about whether any plaintiff will recover anything.

We would rather say that bluntly than let a headline imply otherwise. Every allegation described below is still an allegation, and each one will have to be proven with evidence the court allows a jury to hear.

You will see the words consolidated and centralized used loosely online. Here they describe the same thing: one judge for the pretrial work, with separate cases underneath it.

The Two Theories in These Lawsuits

The complaints press two separate theories. Coverage that explains only the first one leaves out people the litigation is also about.

The first theory is that Dupixent may cause a cutaneous T-cell lymphoma (CTCL), or accelerate one that would otherwise have progressed more slowly. The diagnoses most often named are mycosis fungoides and Sézary syndrome.

The National Cancer Institute describes CTCL as a group of lymphomas that begin in T cells and appear first in the skin.

The second theory is about masking. Early mycosis fungoides can look a lot like eczema, with red, itchy patches that come and go. Plaintiffs allege that by calming the skin, Dupixent may hide the early signs of a lymphoma the patient already had, so the cancer is recognized later than it otherwise would have been.

Neither theory is an established mechanism. Both are under examination, and MDL 3180 is where the expert evidence on each will be argued.

Diagnosed Before You Ever Started Dupixent?

This is the group we worry about most, because they tend to rule themselves out. Someone who reads only about the first theory will assume that a lymphoma present before the first injection ends the conversation.

Under the second theory, it does not automatically end anything. If you were diagnosed before starting Dupixent, or your records show skin findings treated as eczema for years before a biopsy came back as CTCL, the order of events alone does not exclude you.

Whether your timeline fits either theory will turn on details. When symptoms started. Whether earlier biopsies were done, and what they showed. How long you were on the drug. What changed after. Those are records questions, and they get messy, which is the reason to have someone go through them with you.

What the Medical Literature Shows So Far

The research is early, and we are not going to dress it up. Published case reports and observational studies indexed on PubMed have described CTCL diagnoses in patients who had been treated with dupilumab, and some authors have asked whether a lymphoma was already present, and misread as eczema, before treatment began. Those reports describe an association in some patients. They do not establish that the drug caused the cancer, and they do not tell anyone how often it happens.

Some dermatologists have reportedly suggested a skin biopsy before starting Dupixent when a rash looks atypical for eczema. That suggestion bears directly on the masking concern.

If an article tells you the link has been confirmed, look at what it cites. No court has made that finding in this litigation.

If you are currently taking Dupixent, do not stop or change your treatment because of a lawsuit. Talk with your prescribing doctor first. Suspected side effects can be reported to the FDA through its MedWatch program.

What Happens Next in MDL 3180

The proceeding is at its beginning. New MDLs usually open with organizational orders: who leads the plaintiffs’ side, and how complaints and plaintiff fact sheets will be filed. Discovery follows.

The central fight over general causation (whether the science can support either theory at all) typically comes later, decided under the federal rules on expert testimony.

We are not going to guess at a trial date or a case count, and you should be wary of anyone who does at this stage. A federal claim filed now will generally be handled in MDL 3180 while the ground rules are still being written.

If you have already filed somewhere, ask your lawyer how that case relates to the federal proceeding.

One more point. Centralization does not pause your filing deadline. Statutes of limitations vary by state, and in many states the clock can start at diagnosis or when you reasonably connected the diagnosis to the drug.

Records Worth Gathering Now

You do not need all of this before you call. A lawyer can request most of it. But if you have access, these help:

• Pharmacy or specialty-pharmacy records showing when you started and stopped Dupixent
• Dermatology notes from before and after your first dose, including any photos you took of your skin
• Every biopsy and pathology report, especially any that were read as eczema or dermatitis
• Oncology records confirming the CTCL type, such as mycosis fungoides or Sézary syndrome
• A list of other eczema treatments you used before Dupixent, such as topical steroids

If you lost a family member to CTCL after Dupixent treatment, the same records apply, and a wrongful death claim may be available depending on your state’s law.

Take the Next Step

If you or someone you love was treated with Dupixent for eczema or atopic dermatitis and later diagnosed with a cutaneous T-cell lymphoma, including a diagnosis that came before treatment, we will review the timeline with you at no cost. You can read more on our Dupixent lymphoma litigation page, or start with a free case review.

Tell us when the rash started and when the biopsy came back. That is usually where we begin.